With all the promise SPPI has, we have a credibility problem and an apathy problem. Further we have a group of angry longs and former longs bashing SPPI on a daily basis. We also have year over year financials that look bad.
SPPI will likely not get the benefit of the doubt in the near future. The only way to get past the Fusilev sales debacle is for SPPI to deliver on some of the pending milestones. If this occurs we should move closer to fair value which I currently put at $15-20.
Raj resigning, which I don't expect, could boost the PPS, but the real PPS climb will come with more drug approvals and steadily growing revenue that is not Fusilev based.
I'm optimistic about the future, but understand that the PPS will languish until SPPI delivers on NEW advances.